Latest Biotech News

SwRI and Texas Biomed are collaborating to test AI-identified antiviral compounds against Ebola virus, targeting the Bundibugyo species as the strain resurfaces in the Democratic Republic of...

Researchers unveiled an AI system intended to provide just-in-time, risk-stratified evaluations for neonatal sepsis in neonatal intensive care units. The goal is earlier detection during the...

Aspira Women’s Health signed a deal with Cleveland Clinic to expand access to patient samples and accelerate the clinical validation of multiomic diagnostics in women’s health. The collaboration...

Two policy developments are reshaping the regulatory and compliance backdrop for biotech dealmaking tied to China. A separate report said calls for expanding the COINS Act are growing, with...

The FDA approved Beqalzi (sonrotoclax), described as the first BCL2 inhibitor specifically approved for relapsed or refractory mantle cell lymphoma after at least two prior lines of systemic...

A research report highlighted how platinum-antibody conjugates are designed to enhance tumor recognition and immune system engagement, aiming to broaden benefit from immune checkpoint inhibitors....

Medtronic agreed to buy SPR Therapeutics for $650 million, strengthening its pain management portfolio by adding a peripheral nerve stimulation system designed for sustained pain relief. The deal...

Eurobio Scientific struck a distribution agreement with Canhelp Genomics for two molecular oncology assays across the UK, EU, and Benelux. The partnership covers the Canhelp-Uca urine assay for...

Eli Lilly reported early Phase 1 results for its VERVE-102 base-editing program, saying a single infusion reduced LDL cholesterol by as much as 62% and sustained the effect for up to 18 months....

Eli Lilly announced agreements to acquire three private vaccine developers—Vaccine Co., Curevo, and LimmaTech Biologics—expanding its infectious-disease pipeline through a series of transactions...

The FDA granted accelerated approval to Beqalzi (sonrotoclax), becoming the first BCL2 inhibitor approved specifically for relapsed or refractory mantle cell lymphoma after at least two prior...

Lilly’s Phase 1 base-editing results on VERVE-102 are paired with continued momentum in AI-enabled precision approaches for disease biology and clinical decision-making. Separate disclosures from...

Researchers published results supporting continuous fetal monitoring using a wearable ultrasound patch designed to reduce dependence on highly trained sonographers. The work—led by a team...

Lilly’s gene-editing LDL story is part of a broader cardiovascular prevention push that is increasingly shaped by genetics-driven mechanisms and one-time dosing concepts. In parallel, early-stage...

New rules in China are expected to tighten regulatory oversight of investigator-initiated trials (IITs) while clarifying how sponsors can operate legally across modalities beyond cell and gene...

Tennor Therapeutics priced an $80 million IPO in Hong Kong to fund its antibacterial pipeline, including rifasutenizol (TNP-2198), which the company says could support a targeted combination...

Researchers reported that TREM2-positive macrophages detect candidalysin to trigger an early antifungal immune response during oropharyngeal candidiasis. The work, led by Yunsheng Liang at Central...

Kura Oncology disclosed early combination data showing darlifarnib paired with Bristol Myers Squibb’s Krazati delivered response rates up to 69%, according to the company. The update frames the...

Eli Lilly moved to bulk up its infectious-disease pipeline, agreeing to acquire three companies in deals totaling up to $3.8 billion. The acquisitions target viral and bacterial pathogen R&D and...

The FDA granted accelerated approval to Beqalzi (sonrotoclax) for adults with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy,...